No matter whether you are a seasoned programmer or you simply want to take your first steps in writing code, Repl.it wants to help you get from idea to result as fast as possible — without complicated ...
On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...
Replimune Group, Inc. REPL announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ BMY blockbuster ...
SAN DIEGO, Aug. 12, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) ...
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...
Recent discussions on X about Replimune Group Inc. (REPL) have been ignited by the U.S. FDA's rejection of the company's lead drug, RP1, for melanoma treatment in combination therapy. Many users are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results